تعديل

mardi 5 janvier 2016

Gilead's hep B drug succeeds in late-stage trials

(Reuters) - Gilead Sciences Inc said its once-daily experimental hepatitis B drug was found to be as effective as its approved drug, Viread, in two late-stage studies.


http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro

Aucun commentaire:

Enregistrer un commentaire